Biowaiver Courier Ma Gujarati Natak

Halki Diabetes Remedy

Diabetes Alternative Treatment

Get Instant Access

Abdul S, Poddar SS. A flexible technology for modified release of drugs: multi layered tablets. J Control

Release 2004; 97(3):393-405. Abrams J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration. Drugs 1987; 34(3):391-403. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001; 35(7-8):898-907.

Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005; 50(10):1304-12 (discussion 1312). Bach M, Lippold BC. Percutaneous penetration enhancement and its quantification. Eur J Pharm Biopharm 1998; 46(1):1-13.

Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005; 103(4):860-76. Baldi F. Lansoprazole oro-dispersible tablet: pharmacokinetics and therapeutic use in acid-related disorders. Drugs 2005; 65(10):1419-26. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67(1-2):1-5. Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004; 18(6):355-64 (discussion 365-6). Behar-Cohen F. Drug delivery systems to target the anterior segment of the eye: fundamental bases and clinical applications. J Fr Ophtalmol 2002; 25(5):537-44. Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophe-

nolate mofetil. Drugs 2005; 65(8):1037-50. Bejan A, Turcu G. Liposomes: presentation and actual applicative trends in medicine. Rom J Intern Med 1995; 33(3-4):141-9.

Benninger MS. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. Expert Opin Pharmac-other 2003; 4(10):1839-46.

Bernkop-Schnurch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 2003; 93(2):95-103. Bianchi PG, Parente F. Antacids for duodenal ulcer: current role. Antacids for duodenal ulcer: current role. Scand J Gastroenterol Suppl 1990; 174:48-53.

Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 2002; 5(1):59-71.

Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development. Pharm Dev Technol 1997; 2(2):95-109.

Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5(26):1-149.

Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5(6):1333-45.

Bunker M, Davies M, Roberts C. Towards screening of inhalation formulations: measuring interactions with atomic force microscopy. Expert Opin Drug Deliv 2005; 2(4):613-24.

Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 2005; 4(6):461-7.

Cabrera J, Redondo P, Becerra A, et al. Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004; 140(6):667-73.

Chang TM. Artificial cells with emphasis on bioencapsulation in biotechnology. Biotechnol Annu Rev 1995; 1:267-95.

Chaubal MV. Application of drug delivery technologies in lead candidate selection and optimization. Drug Discov Today 2004; 9(14):603-9.

Chen D, Maa YF, Haynes JR. Needle-free epidermal powder immunization. Expert Rev Vaccines 2002; 1(3):265-76.

Chew NY, Chan HK. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 2002; 15(3):325-30.

Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003; 6(1):33-66.

Cleland JL. Protein delivery from biodegradable microspheres. Pharm Biotechnol 1997; 10:1-43.

Cole P. Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms. Clin Ther 1997; 19(4):617-25 (discussion 603).

Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 2004; 56(9):1243-55.

Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002; 19(4-5):425-98.

Dahlof B, Andersson OK. A felodipine-metoprolol extended-release tablet: its properties and clinical development. J Hum Hypertens 1995; 9(Suppl. 2):S43-7.

Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005; 65(2):285-302.

Darkes MJ, Perry CM. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2003; 2(2):175-201.

Davis SS. Coming of age of lipid-based drug delivery systems. Adv Drug Deliv Rev 2004; 56(9):1241-2.

Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003; 42(13):1107-28.

De Moor R, Verbeeck R, Martens L. Evaluation of long-term release of fluoride by type II glass ionomer cements with a conventional hardening reaction. Rev Belge Med Dent 1996; 51(3):22-35.

Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 1989; 39(11 Suppl. 2):20-4.

Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005; 39(10):1667-77 (Epub 2005 August 23).

Dhaon NA. Amoxicillin tablets for oral suspension in the treatment of acute otitis media: a new formulation with improved convenience. Adv Ther 2004; 21(2):87-95.

Digenis GA, Gold TB, Shah VP. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci 1994; 83(7):915-21.

Doelker E. Recent advances in tableting science. Boll Chim Farm 1988; 127(2):37-49.

Doelker E, Massuelle D. Benefits of die-wall instrumentation for research and development in tabletting. Eur J Pharm Biopharm 2004; 58(2):427-44.

Dowson AJ, Almqvist P. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin 2005; 21(Suppl. 3):S13-17.

Duchene D, Ponchel G. Principle and investigation of the bioadhesion mechanism of solid dosage forms. Biomaterials 1992; 13(10):709-14.

DuPont HL. Nonfluid therapy and selected chemoprophylaxis of acute diarrhea. Am J Med 1985; 78(6B):81-90.

DuPont HL. Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 1987; 21(9):687-93.

Faassen F, Vromans H. Biowaivers for oral immediate-release products: implications of linear pharmacokinetics. Clin Pharmacokinet 2004; 43(15):1117-26.

Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005; 57(2):303-16.

Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 1998; 24(11):979-93.

Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 2005; 19(3):179-87.

Figgitt DP, Plosker GL. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs 2000; 60(2):481-516.

Flores NA. Ezetimibe + simvastatin (Merck/Schering-Plough). Curr Opin Investig Drugs 2004; 5(9):984-92.

Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004; 1(1):67-86.

Frishman WH, Sherman D, Feinfeld DA. Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS. Cardiol Clin 1987; 5(4):703-16.

Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004; 21(6):433-76.

Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41(11):801-11.

Gallen CC. Strategic challenges in neurotherapeutic pharmaceutical development. NeuroRx 2004; 1(1):165-80.

Garg S, Kandarapu R, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 2003; 17(1):17-32.

Garg S, Tambwekar KR, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges. AIDS Patient Care STDS 2003; 17(8):377-99.

Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177(4):437-47.

Gill J, Feinberg J. Saquinavir soft gelatin capsule: a comparative safety. Drug Saf 2001; 24(3):223-32.

Gillis JC, Benfield P, Goa KL. Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 1995; 50(1):157-75.

Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther 1999; 21(4):634-42.

Goldenheim PD, Conrad EA, Schein LK. Treatment of asthma by a controlled-release theophylline tablet formulation: a review of the North American experience with nocturnal dosing. Chronobiol Int 1987; 4(3):397-408.

Goldstein JL, Larson LR, Yamashita BD. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/miso-prostol. Am J Manage Care 1998; 4(5):687-97.

Gooding OW. Process optimization using combinatorial design principles: parallel synthesis and design of experiment methods. Curr Opin Chem Biol 2004; 8(3):297-304.

Goodnow RA, Jr. Current practices in generation of small molecule new leads. J Cell Biochem Suppl 2001; (Suppl. 37) 13-21.

Gotfried MH. Clarithromycin (Biaxin) extended-release tablet: a therapeutic. Expert Rev Anti Infect Ther 2003; 1(1):9-20.

Gregoriadis G. Liposomes as a drug delivery system: optimization studies. Adv Exp Med Biol 1988; 238:151-9 (No abstract available).

Grosdidier J, Boissel P, Bresler L, Vidrequin A. Stenosing and perforated ulcers of the small intestine related to potassium chloride in enteric-coated tablets. Apropos of 11 cases. Chirurgie 1989; 115(3):163-9 (French).

Grzeszczak W. Cardura XL—a unique drug formulation—doxazosine administered in a slow-release form (doxazosine GITS). Przegl Lek 2000; 57(11):643-54.

Gudgin Dickson EF, Goyan RL, Pottier RH. New directions in photodynamic therapy. Cell Mol Biol (Noisy-le-grand) 2002; 48(8):939-54.

Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5(6):1385-98.

Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999; 184(1):1-6.

Haefner S, Knietsch A, Scholten E, Braun J, Lohscheidt M, Zelder O. Biotechnological production and applications of phytases. Appl Microbiol Biotechnol 2005; 68(5):588-97 (Epub 2005 October 26).

Harashima H, Shinohara Y, Kiwada H. Intracellular control of gene trafficking using liposomes as drug carriers. Eur J Pharm Sci 2001; 13(1):85-9.

Harashima H, Ishida T, Kamiya H, Kiwada H. Pharmacokinetics of targeting with liposomes. Crit Rev Ther Drug Carrier Syst 2002; 19(3):235-75.

Hardy IJ, Fitzpatrick S, Booth SW. Rational design of powder formulations for tamp filling processes. J Pharm Pharmacol 2003; 55(12):1593-9.

Harsch IA. Inhaled insulins: their potential in the treatment of diabetes mellitus. Treat Endocrinol 2005; 4(3):131-8.

Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res 2002; 19(10):1389-99.

Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 2003; 52(Suppl. 1):S3-15 (Epub 2003 June 18).

Heinig R. Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet 1998; 35(3):191-208 (Erratum in: Clin Pharmacokinet 1998 November; 35(5):390).

Hiestand EN. Mechanical properties of compacts and particles that control tableting success. J Pharm Sci 1997; 86(9):985-90.

Hirata K, Iwanami H. The role of triptans and analgesics for primary headache treatment. Nippon Rinsho 2005; 63(10):1797-801 (Japanese).

Hirschberger R. Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies. Fortschr Med 1993; 111(30):481-4.

Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Rel 2000; 65(1-2):63-71.

Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature. Pharmacotherapy 2005; 25(6):886-92.

Jones DH, Partidos CD, Steward MW, Farrar GH. Oral delivery of poly(lactide-co-glycolide) encapsulated vaccines. Behring Inst Mitt 1997;(98):220-8.

Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 2004; 21(11):1955-69.

Kalia YN, Guy RH. Modeling transdermal drug release. Adv Drug Deliv Rev 2001; 48(2-3):159-72.

Kanjickal DG, Lopina ST. Modeling of drug release from polymeric delivery systems—a review. Crit Rev Ther Drug Carrier Syst 2004; 21(5):345-86.

Karlsson L, Torstensson A, Taylor LT. The use of supercritical fluid extraction for sample preparation of pharmaceutical formulations. J Pharm Biomed Anal 1997; 15(5):601-11.

Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm 2002; 28(5):473-93.

Kleinebudde P. Roll compaction/dry granulation: pharmaceutical applications. Eur J Pharm Biopharm 2004; 58(2):317-26.

Knop K. Active ingredient release from solid drug forms—test methods, evaluation, influencing parameters. Pharm Unserer Zeit 1999; 28(6):301-8 (German).

Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004; 26(12):1994-2002.

Kostarelos K. Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. Adv Colloid Interface Sci 2003; 106:147-68.

Kozubek A, Gubernator J, Przeworska E, Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 2000; 47(3):639-49.

Kuhlmann J. Alternative strategies in drug development: clinical pharmacological aspects. Int J Clin Pharmacol Ther 1999; 37(12):575-83.

Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 1995; 12(3):229-46.

Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56(6):600-12.

Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50(9):1161-76.

Leuenberger H. New trends in the production of pharmaceutical granules: batch versus continuous processing. Eur J Pharm Biopharm 2001; 52(3):289-96.

Levy RA. Therapeutic inequivalence of pharmaceutical alternates. Am Pharm 1985; NS25(4):28-39.

Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002; 63(3):162-5.

Maa YF, Prestrelski SJ. Biopharmaceutical powders: particle formation and formulation considerations. Curr Pharm Biotechnol 2000; 1(3):283-302.

Machida Y. Development of topical drug delivery systems utilizing polymeric materials. Yakugaku Zasshi 1993; 113(5):356-68 (Japanese).

Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets 2004; 5(5):449-55.

Man M, Rugo H. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs 2005; 8(9):739-54.

Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin Drug Deliv 2005; 2(5):855-71.

McKay B, Hoogenraad M, Damen EW, Smith AA. Advances in multivariate analysis in pharmaceutical process development. Curr Opin Drug Discov Devel 2003; 6(6):966-77.

Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3):165-96.

Melia CD, Davis SS. Review article: mechanisms of drug release from tablets and capsules. 2. Dissolution. Aliment Pharmacol Ther 1989; 3(6):513-25.

Michele TM, Knorr B, Vadas EB, Reiss TF. Safety of chewable tablets for children. J Asthma 2002; 39(5):391-403.

Mooradian AD. Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments. Treat Endocrinol 2004; 3(5):279-87.

Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Des 2002; 8(6):441-54.

Morissette SL, Almarsson O, Peterson ML, et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 2004; 56(3):275-300.

Nagai T. New drug development by innovative drug administration—"change" in pharmaceutical field. Yakugaku Zasshi 1997; 117(10-11):963-71.

Nail SL, Jiang S, Chongprasert S, Knopp SA. Fundamentals of freeze-drying. Pharm Biotechnol 2002; 14:281-360.

Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002; 24(12):2022-50.

Nishida K. Development of drug delivery system based on a new administration route for targeting to the specific region in the liver. Yakugaku Zasshi 2003; 123(8):681-9 (Japanese).

Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs 2004; 18(8):505-20.

Nuijen B, Bouma M, Schellens JH, Beijnen JH. Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 2001; 19(2):143-53.

Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005; 59(6):674-6.

Odegard PS, Capoccia KL. Inhaled insulin: Exubera. Ann Pharmacother 2005; 39(5):843-53 (Epub 2005 April 12).

O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003; 2(2):269-83.

Okada N. Design and creation of cytomedicine for application to cell therapy. Yakugaku Zasshi 2005; 125(8):601-15 (Japanese).

Ormrod D, Goa KL. Intranasal metoclopramide. Drugs 1999; 58(2):315-22 (discussion 323-4).

Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20(11):886-98.

Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, et al. Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004; 26(9):703-21.

Pathak P, Meziani MJ, Sun YP. Supercritical fluid technology for enhanced drug delivery. Expert Opin Drug Deliv 2005; 2(4):747-61.

Patro SY, Freund E, Chang BS. Protein formulation and fill-finish operations. Biotechnol Annu Rev 2002; 8:55-84.

Pawar R, Ben-Ari A, Domb AJ. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther 2004; 4(8):1203-12.

Perkins AC, Frier M. Nuclear medicine techniques in the evaluation of pharmaceutical formulations. Pharm World Sci 1996; 18(3):97-104.

Perkins AC, Frier M. Radionuclide imaging in drug development. Curr Pharm Des 2004; 10(24):2907-21.

Pettipher R, Cardon LR. The application of genetics to the discovery of better medicines. Pharmacoge-nomics 2002; 3(2):257-63.

Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations. Med Device Technol 1990; 1(5):48-55 (Erratum in: Med Device Technol 1990-November-December; 1(6):33).

Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems: part II: system design considerations. Med Device Technol 1990; 1(6):28-33.

Rabiskova M, Vostalova L, Medvecka G, Horackova D. Hydrophilic gel matrix tablets for oral administration of drugs. Ceska Slov Farm 2003; 52(5):211-7 (Czech).

Ram CV, Featherston WE. Calcium antagonists in the treatment of hypertension. An overview. Chest 1988; 93(6):1251-3.

Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv 2005; 2(4):341-51.

Ranade VV. Drug delivery systems 5B. Oral drug delivery. J Clin Pharmacol 1991; 31(2):98-115.

Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34(7-8):915-23.

Reeves RR, Wallace KD, Rogers-Jones C. Orally disintegrating olanzapine: a possible alternative to injection of antipsychotic drugs. J Psychosoc Nurs Ment Health Serv 2004; 42(5):44-8.

Richard A, Margaritis A. Poly(glutamic acid) for biomedical applications. Crit Rev Biotechnol 2001; 21(4):219-32.

Ritschel WA. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin Transplant 1996; 10(4):364-73.

Sable D, Murakawa gJ. Quinolones in dermatology. Dis Mon 2004; 50(7):381-94.

Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005; 10(2):139-47.

Schmidt PC, Christin I. Effervescent tablets—a nearly forgotten drug form. Pharmazie 1990; 45(2):89-101.

Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2005; 4(8):649-63.

Schumacher HR, Jr. Ketoprofen extended-release capsules: a new formulation for the treatment of osteoarthritis and rheumatoid arthritis. Clin Ther 1994; 16(2):145-59.

Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50(4):375-82.

Sezaki H. Drug delivery systems. Gan To Kagaku Ryoho 1985; 12(11):2077-82.

Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56(23 Suppl. 4):S18-21 (Erratum in: Am J Health Syst Pharm 2000 April 1; 57(7):699).

Sharpe M, Ormrod D, Jarvis B. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. Am J Cardiovasc Drugs 2002; 2(2):125-32 (discussion 133-4).

Shigeyama M. Preparation of a gel-forming ointment base applicable to the recovery stage of bedsore and clinical evaluation of a treatment method with different ointment bases suitable to each stage of bedsore. Yakugaku Zasshi 2004; 124(2):55-67 (Japanese).

Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 2001; 48(2-3):229-47.

Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005; 22(1):27-105.

Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." Part II: retrospect and prospects. Crit Rev Ther Drug Carrier Syst 2005; 22(3):215-94.

Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects—an update. J Pharm Pharmacol 2001; 53(8):1047-67.

Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235(1-2):179-92.

Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003; 18(1):3-18.

Smart JD. Buccal drug delivery. Expert Opin Drug Deliv 2005; 2(3):507-17.

Song H, Guo T, Zhang R, et al. Preparation of the traditional Chinese medicine compound recipe heart-protecting musk pH-dependent gradient-release pellets. Drug Dev Ind Pharm 2002; 28(10):1261-73.

Speiser PP. Nanoparticles and liposomes: a state of the art. Methods Find Exp Clin Pharmacol 1991; 13(5):337-42.

Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21(2):201-30.

Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev 2003; 55(9):1201-15.

Swainston HT, Keating GM. Extended-release carbamazepine capsules: in bipolar I disorder. CNS Drugs 2005; 19(8):709-16.

Takada S, Ogawa Y. Design and development of controlled release of drugs from injectable microcapsules. Nippon Rinsho 1998; 56(3):675-9.

Takakura Y, Nishikawa M, Yamashita F, Hashida M. Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. J Drug Target 2002; 10(2):99-104.

Takayama K, Fujikawa M, Nagai T. Artificial neural network as a novel method to optimize pharmaceutical formulations. Pharm Res 1999; 16(1):1-6.

Takayama K, Fujikawa M, Obata Y, Morishita M. Neural network based optimization of drug formulations. Adv Drug Deliv Rev 2003; 55(9):1217-31.

Takeuchi H, Thongborisute J, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv Drug Deliv Rev 2005; 57(11):1583-94 (Epub 2005 September 16).

Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm 2004; 277(1-2):31-7.

Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992; 44(2):251-77.

Toguchi H, Ogawa Y, Okada H, Yamamoto M. Once-a-month injectable microcapsules of leuprorelin acetate. Yakugaku Zasshi 1991; 111(8):397-409.

Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004; 26(3):137-42.

Tye H. Application of statistical 'design of experiments' methods in drug discovery. Drug Discov Today 2004; 9(11):485-91.

Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm 2004; 58(2):279-89.

Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs 2001; 61(15):2221-8 (discussion 2229-30).

Wagstaff AJ, Figgitt DP. Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation. Treat Endocrinol 2004; 3(5):327-32.

Wassef NM, Alving CR, Richards RL. Liposomes as carriers for vaccines. Immunomethods 1994; 4(3):217-22.

Wellington K. Rosiglitazone/Metformin. Drugs 2005; 65(11):1581-92 (discussion 1593-4).

Wernsdorfer WH. Coartemether (artemether and lumefantrine): an oral antimalarial drug. Expert Rev Anti Infect Ther 2004; 2(2):181-96.

White NS, Errington RJ. Fluorescence techniques for drug delivery research: theory and practice. Adv Drug Deliv Rev 2005; 57(1):17-42.

Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26(3):159-69.

Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56(9):1257-72.

Wouters J, Ooms F. Small molecule crystallography in drug design. Curr Pharm Des 2001; 7(7):529-45.

Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 1998; 87(7):787-96.

Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27(1):1-12.

Yilmaz E, Borchert HH. Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema—an in vivo study. Int J Pharm 2006; 307(2):232-8 (Epub 2005 November 11).

Young SS, Lam RL, Welch WJ. Initial compound selection for sequential screening. Curr Opin Drug Discov Devel 2002; 5(3):422-7.

Zargar A, Basit A, Mahtab H. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan. J Indian Med Assoc 2005; 103(8):444-6.

Zhang GG, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 2004; 56(3):371-90.

Zimmermann U, Mimietz S, Zimmermann H, et al. Hydrogel-based non-autologous cell and tissue therapy. Biotechniques 2000; 29(3):564-72 (574, 576 passim).

Was this article helpful?

0 0
Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment